Effects of antiretroviral therapy on occurrence of pre-eclampsia [3]

Lancet

Volumn 361, Issue 9354, 2003, Pages 347-348

  Mawson, Anthony R ^a  

^a JACKSON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; FETAL ANTIGEN; RETINOID; RETINOL; RETINOL BINDING PROTEIN; RETINOL ESTER;

CELL DAMAGE; CHOLESTASIS; CONCENTRATION (PARAMETERS); DISEASE ASSOCIATION; GLUCOSE TOLERANCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; LETTER; LIVER CELL; LIVER TOXICITY; PREECLAMPSIA; PREGNANCY; PRIORITY JOURNAL; PROTEIN SECRETION;

EID: 0037464727     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)12359-8     Document Type: Letter

References (5)

1. Wimalasundera R.C., Larbalestier N., Smith J.H., et al. Pre-eclampsia, antiretroviral therapy, and immune reconstitution. Lancet. 360:2002;1152-1154.
2. Buscarat F., Prevot M.-H. Alopecia associated with indinavir therapy. N Engl J Med. 341:1999;618.
3. Chmait R., Franklin P., Spector S.A., Hull A.D. Protease inhibitors and decreased birth weight in HIV-infected pregnant women with impaired glucose tolerance. J Perinatol. 22:2002;370-373.
4. Toma E., Devost D., Chow Lan N., Bhat P.V. HIV-protease inhibitors alter retinoic acid synthesis. AIDS. 15:2001;1979-1984.
5. Shey W.I., Brocklehurst P., Sterne J.A. Vitamin A supplementation for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database Syst Rev. 3:2002;CD003648.